News

Nova Mentis Applies to US FDA for Psilocybin Orphan Drug Designation Fragile X Syndrome Treatment

Vancouver, British Columbia – September 14, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce it has filed an application with the U.S. Food and Drug Administration (FDA)
Read More »

Nova Mentis to Present at the H.C. Wainwright Global Investment Conference

Vancouver, British Columbia – September 9, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for chronic inflammatory disorders, is pleased to announce that it will present at the H.C. Wainwright 23rd Annual Global Investment
Read More »

Nova Mentis Expands Psilocybin Research Program Targets Obesity and Diabetes

Vancouver, British Columbia – September 7, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it is expanding its psilocybin research and development program to target obesity
Read More »

Nova Mentis Files Fragile X Orphan Drug Designation with European Medicines Agency

Vancouver, British Columbia – August 12, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce it has filed for orphan drug designation with the European Medicines Agency (EMA) for its propriety psilocybin
Read More »

Glow Acquires Strategic Equity Investment in Nova Mentis

TORONTO, Ontario -August 10, 2021 – Glow LifeTech Corp. (CSE: GLOW) (FSE: 9DO) (“Glow” or the “Company”), a biotech company focused on producing next-generation, science-backed natural ingredients, is pleased to announce a strategic investment into Nova Mentis1 (“Nova”). The Company purchased 854,000 shares in Nova at an average cost of $0.12 CAD. Nova Mentis Life Science Corp. is a Canadian-based biotechnology company
Read More »

Nova Mentis Files U.S. Patent Application for Psilocybin-Based Therapeutics

Vancouver, British Columbia – July 29, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce it has filed a U.S. provisional patent application for a proprietary manufacturing process for the production of
Read More »